Business Directory, Press Releases, Jobs, Products, Services, Articles
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | News on Your Site

Press Releases

Affinity Biologicals

Press Release

Receive press releases from Affinity Biologicals: By Email RSS Feeds:

Affinity Biologicals Inc. Has Become a Primary Manufacturer of Polyclonal Antibodies Used in Hemostasis & Thrombosis Research Around the World

Affinity Biologicals, the Ontario-based company has gradually become the primary manufacturer of Hemostasis & Thrombosis related polyclonal antibodies, which are delivered for research and diagnosis around the world.

Ancaster, Canada, March 12, 2014 --( Over a substantial amount of time and extensive research, Affinity Biologicals has produced a wide variety of polyclonal antibodies that are supplied to research institutes, laboratories and pharmaceutical companies throughout the globe. The company specializes in products used in hemostasis, thrombosis and fibrinolysis research around the world, with over 250 products that include a wide range of conjugates, a full-line of human plasma products, ELISA kits and matched-pair antibodies. Though Affinity Biologicals has increased its offering by growing their product listing and continued development of quality polyclonal antibodies.

In an interview, a spokesperson from Affinity Biologicals said, "Through extensive research and thorough testing we have been able to create a diverse line of high quality antibodies which we send to a number of customers around the world. We have a great team of skilled professionals and it is their efforts that we have been able to reach this benchmark. We are proud to be one of the primary global suppliers of quality polyclonal antibodies within our field of research."

Some of Affinity Biologicals Inc.’s polyclonal antibodies include Plasminogen, Prothrombin, ATIII, PAI-1, Kininogen, Protein C, Protein S, Vimentin and Alpha 2- Macroglobulin. Apart from maintaining a wide variety of polyclonal antibodies, Affinity Biologicals offers a number of options in terms of concentration and the hosts, which means more than often, customers can find what they are specifically looking for.

Affinity Biologicals Inc. utilizes polyclonal antibodies for their products, so is there space for monoclonal antibodies within their product offering? The spokesperson explained, "Thinking about the expenses and the time required to produce monoclonal antibodies, it is a big investment. Producing monoclonal antibodies requires advanced equipment and technology and the continual retraining of production scientists. Added to that, the hybridoma methodology takes a great deal longer to produce antibodies as contrasted with polyclonal antibody production process."

He included, "Then again, polyclonal antibodies production is relatively straight forward, given that they are naturally produced within the host animal and yield large volumes of serum. Another benefit polyclonal antibodies offer is the non-specific antibodies in a single batch, which are able to target multiple epitopes on a single antigen."

Affinity Biologicals also offers all the antibodies in a number of formats and variants, which mainly differ in the concentration levels and suspensions. Their three main formats for polyclonal antibodies are Whole IgG, Affinity-Purified IgG and Enzyme Labelled IgG, which consist of the base level antibody and differ in purity and conjugations.

Affinity Biologicals recently released a number of new products as well, like VisuLize™ Factor XI Antigen ELISA Kit, VisuDep™-F Frozen Factor II Deficient Plasma, VisuDep™-F Frozen Factor V Deficient Plasma, VisuDep™-F Frozen Factor VII Deficient Plasma, VisuDep™-F Frozen Factor VIII Deficient Plasma, VisuDep™-F Frozen Factor IX Deficient Plasma, VisuDep™-F Frozen Factor X Deficient Plasma, VisuDep™-F Frozen Factor XI Deficient Plasma, VisuCon™-F Frozen Coag Screen N (Normal Pooled Plasma), VisuCon™-F Frozen Coag Screen ABN, Canine Factor VIII antibodies, VisuCon™ -F Frozen Unassayed Normal Control Plasma, and VisuCon™ -F Frozen Unassayed Abnormal Control 1 Plasma. All these products come with the guarantee of high quality and purity according to Affinity Biologicals.

To learn more, visit their website

About The Company
Started in 1987, by the principals Hugh and Patricia Hoogendoorn, with strong background in research related to hemostasis and extensive research in reagent development, Affinity Biologicals Inc. has become a leading manufacturer of more than 250 reagents used in the diagnostics and research of thrombosis and hemostasis. Their product line includes coagulation antibodies, matched-pair antibody sets for ELISA, depleted and deficient plasmas, protease inhibitor deficient plasmas, the trademarked VisuLize™ line of complete Elisa kits and the VisuCon™ coagulation controls, VisuCal™ calibrator plasma and VisuDep™ Deficient Plasmas.

Apart from the ISO 13485:2003 registered quality system, Affinity Biologicals Inc. is a licensed medical device manufacturer recognized by the US Food and Drug Administration, Health Canada and European regulatory authorities.

Contact Details
Affinity Biologicals Inc.
Address: 1395 Sandhill Drive, Ancaster, ON, Canada L9G 4V5.
Email: Website:
Tel: (905) 304-9896
Fax: (905) 304-9897
Toll Free: 1-800-903-6020
Contact Information
Affinity Biologicals
Hugh Hoogendoorn
(905) 304-9896

Click here to view the list of recent Press Releases from Affinity Biologicals
Promote Your Business